Literature DB >> 8846513

Long-term ouabain administration does not alter blood pressure in conscious Sprague-Dawley rats.

M Li1, A Martin, C Wen, S W Turner, L K Lewis, J A Whitworth.   

Abstract

1. We tested the ability of ouabain to cause chronic hypertension by continuously infusing ouabain for 28 days (miniosmotic pump implantation; i.p.). The blood pressure and metabolic effects of sham (150 mmol/L NaCl; n = 12) or ouabain infusion (10 micrograms/kg per day; n = 14; 100 micrograms/kg per day; n = 14) were examined in conscious Sprague-Dawley rats. 2. Plasma ouabain concentrations measured after 28 days of ouabain infusion were as follows: sham, not detectable (n = 11); ouabain 10 micrograms/kg per day, 0.60 +/- 0.07 nmol/L (n = 14); and ouabain 100 micrograms/kg per day, 7.17 +/- 0.57 nmol/L (n = 14; P < 0.001). 3. Sham or ouabain infusion did not alter food intake, bodyweight, water intake or urine output in conscious rats. 4. Blood pressure was not altered by sham treatment. Ouabain at 10 micrograms/kg per day or 100 micrograms/kg per day did not produce consistent rises in blood pressure. Ouabain at 10 micrograms/kg per day increased blood pressure on treatment day 12 only (+6 mmHg; P < 0.05), while at 100 micrograms/kg per day blood pressure increased on treatment days 16 (+9 mmHg; P < 0.05) and day 18 (+8 mmHg; P < 0.05) only. There was no significant difference in blood pressure between sham and ouabain groups. 5. Renal blood flow was decreased in rats infused with ouabain at 10 micrograms/kg per day (2.0 +/- 0.3 mL/min per 100 g bodyweight; n = 5; P < 0.01) and 100 micrograms/kg per day (2.2 +/- 0.4 mL/min per 100 g bodyweight; n = 7; P < 0.05) compared with sham treatment (3.5 +/- 0.2 mL/min per 100 g bodyweight; n = 6). Renal vascular resistance was increased in rats treated with ouabain at 10 micrograms/kg per day (65.5 +/- 12.6 mmHg/mL per min per 100 g bodyweight; n = 5; P < 0.01) and 100 micrograms/kg per day (66.0 +/- 15.6 mmHg/mL per min per 100 g bodyweight; n = 7; P < 0.05) compared with sham treatment (32.6 +/- 2.5 mmHg/mL per min per 100 g bodyweight; n = 6). 6. High plasma concentrations of ouabain do not cause consistent increases in blood pressure in conscious Sprague-Dawley rats.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8846513     DOI: 10.1111/j.1440-1681.1995.tb02327.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  4 in total

1.  Effects of long-term ouabain treatment on blood pressure, sodium excretion, and renal dopamine D(1) receptor levels in rats.

Authors:  Yurong Zhang; Zuyi Yuan; Heng Ge; Yanping Ren
Journal:  J Comp Physiol B       Date:  2009-07-22       Impact factor: 2.200

2.  Alterations in phenylephrine-induced contractions and the vascular expression of Na+,K+-ATPase in ouabain-induced hypertension.

Authors:  Luciana V Rossoni; Mercedes Salaices; Jesús Marín; Dalton V Vassallo; María J Alonso
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

3.  Increased constrictor tone induced by ouabain treatment in rats.

Authors:  Victor M Pulgar; Anne B Jeffers; Hanadi M Rashad; Debra I Diz; Azeez A Aileru
Journal:  J Cardiovasc Pharmacol       Date:  2013-08       Impact factor: 3.105

4.  Contribution of the endothelin and renin-angiotensin systems to the vascular changes in rats chronically treated with ouabain.

Authors:  Fabiano E Xavier; Alvaro Yogi; Gláucia E Callera; Rita C Tostes; Yolanda Alvarez; Mercedes Salaices; María J Alonso; Luciana V Rossoni
Journal:  Br J Pharmacol       Date:  2004-10-11       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.